Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Assistant Professor in Thoracic Oncology and Developmental Therapeutics at the University of Colorado Anschutz Cancer Center. Interests include clinical trial design, teaming with translational scientists and education. Has participated as a local principal investigator on cooperative group studies, studies involving agents targeting the RAS pathway (SHP2 inhibitors, KRAS G12C inhibitors), and antibody drug conjugates. Has published approximately 40 peer reviewed articles to date. Hobbies include hiking and fitness.
Published in
Speakers
Dr. Owonikoko is a Professor and Vice Chair for Faculty Development in the Department of Hematology and Medical Oncology at Emory University. He is also a Georgia Research Alliance Distinguished Cancer Scientist. He received his medical degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991 and a doctoral degree in Anatomic Pathology from the Heinrich Heine University, Dusseldorf, Germany in 2000. He was a postdoctoral research fellow at the Johns Hopkins University in Baltimore, USA from 2000 to 2002. He completed Internal Medicine residency training at the Graduate Hospital, Drexel University in Philadelphia in 2005 followed by a clinical fellowship in Hematology/Medical Oncology at the University of Pittsburgh in 2008. He has been on faculty at Emory University since 2008 and has focused his translational research activities on lung cancer, thyroid cancer and early phase drug development. Dr. Owonikoko has received peer-reviewed grant funding from the NIH, DOD and Georgia Cancer Coalition. He has published over 227 peer-reviewed manuscripts in high impact journals including New England Journal of Medicine, Cell, Science, Nature, CA Cancer Journal, Cancer Cell, Lancet Oncology, JCO, Cancer Discovery, Nature Communications, Oncogene, Cancer Research, Clinical Cancer Research and Journal of Thoracic Oncology.
Published in
Speakers
Dr. Owen is a clinical investigator focusing on novel therapeutic interventions for patients with thoracic malignancies. Dr. Owen designed and opened several early phase clinical trials as investigator-initiated studies, ranging from single-site phase I studies to national NCI-CTEP phase I/II trials. Dr. Owen has been collaborating with translational research teams to develop and conduct a phase I study in patients with NSCLC targeting the adenosine pathway with an oral immunotherapy titled “PBF-1129 in patients with advanced Non-Small Cell Lung Cancer (NSCLC)” (NCT03274479). Dr. Owen has worked to better understand the unique toxicities that occur in patients treated with immunotherapies and strategies to predict and mitigate these toxicities.
Published in
Speakers
Health Science Clinical Professor at University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center at Orange, California, USA. Associate Editor at JTO and JTO-CRR. Clinical interests in phase 1 targeted therapy trials, molecular epidemiology of RTK-fusions and ligand fusions, and overcoming resistances to targeted therapy.
Published in
Speakers
I've been at OSU/James for 20 years, previously having done my fellowship at NCI. Currently focused on translational therapeutics.
Published in
Speakers
Dr. Osarogiagbon currently serves as Director of the Multidisciplinary Thoracic Oncology Program at the Baptist Cancer Center, in Memphis, Tennessee. He also serves as Director of the Thoracic Oncology Research (ThOR) Group of the Baptist Cancer Center and is the Principal Investigator of three ongoing National Institutes of Health-funded research projects, as well as IH-1304-6147, a recently completed Patient Centered Outcomes Research Institute-funded comparative effectiveness study of multidisciplinary v serial care for lung cancer titled ‘Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology.’ Dr. Osarogiagbon’s research interests center around improving population-level outcomes of cancer care by improving systems of care-delivery, improving the accuracy of cancer staging and evaluating the biologic drivers of outcome differences in potentially curable lung cancer. He is a member of the Cancer Prevention Steering Committee of the National Cancer Institute and a member of the Staging and Prognostic Factors and the Strategic Planning Committees of the International Association for the Study of Lung Cancer.
Published in
Speakers
Dr. Joel Neal, MD, PhD, is Associate Professor of Medicine (Oncology) at the Stanford Cancer Institute in Palo Alto, California, United States. He maintains an active thoracic medical oncology practice, and also directs the Stanford Thoracic Clinical Research Group which focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer, mesothelioma, and other thoracic malignancies. He participates in the IASLC Continuing Medical Education Committee, and as an active member of the ECOG-ACRIN national cooperative group, he has chaired multiple lung cancer studies. He also serves as IT medical director of Stanford Cancer Center.
Published in
Speakers
Dr. Jarushka Naidoo is a Consultant Medical Oncologist at Beaumont Hospital, Dublin (Ireland) and an Adjunct Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Center for Cancer Immunotherapy, at Johns Hopkins University, in Baltimore, MD. Dr. Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed both internal medicine training and a medical oncology fellowship through the Royal College of Physicians of Ireland. She then completed an awarded advanced fellowship at Memorial Sloan Kettering Cancer Center (New York), and joined the faculty at Johns Hopkins University in 2015. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related adverse events, and was the co-chair of the multidisciplinary Johns Hopkins Immune-related Toxicity Team. She recently returned to Ireland to lead the lung cancer program at Beaumont Hospital (Dublin) and the Royal College of Surgeons of Ireland. She will also serve as the new chair of the thoracic committee for Cancer Trials Ireland, where she will direct and lead the national clinical trial program for lung and thoracic cancers.
Dr. Naidoo currently leads investigator-initiated trials for patients with lung cancer, specifically for those with stage III non-small lung cancer, and those with CNS metastases. She is the Chair of the Immunotherapy Subcommittee of the NRG Clinical Trials Cooperative Group and serves on the ASCO and SITC Immune-Related Toxicity Guideline Panels. She is the recipient of several grants and awards.
Published in
Speakers
Dr. Misako Nagasaka is a thoracic oncologist and a clinical investigator at the Karmanos Cancer Institute, located in Detroit, Michigan. She is also an assistant professor at the Wayne State University School of Medicine, Department of Oncology. Her clinical and research interests are in molecular targeted therapy and immunotherapy in thoracic and head and neck malignancies, with a special focus in medical ethics. She serves as the site principal investigator (PI) for over 20 active clinical trials and enjoys collaborating with other PIs across the country and around the world.
Published in
Speakers
Dr. Minna is Director of the Hamon Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at The University of Texas Southwestern Medical Center. He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. He graduated from Stanford Medical School where he did research with Dr. Leonard Herzenberg, was a resident at Massachusetts General Hospital, a Research Associate at the National Heart Lung and Blood Institute (under Dr. Marshal Nirenberg), Chief of the Section of Somatic Cell Genetics, Chief of the NCI-VA and then NCI-Navy Medical Oncology Branches at the National Cancer Institute (1975-1991). His work focused on understanding the molecular pathogenesis of lung cancer and translating this into the clinic. He has trained many investigators in lung cancer research, and led a joint Lung Cancer NCI Special Program of Research Excellence (SPORE) grant between UTSW and the MD Anderson Cancer Center and is part of NCI and Texas Cancer Prevention and Research Institute (CPRIT) multi-investigator grants to discover new therapeutic approaches and personalized medicine for lung cancer. He co-leads the Experimental Therapeutics Program for the UTSW Simmons Cancer Center.
Published in
Speakers
